Successful treatment for Hodgkin's lymphoma in a female patient with Ph+ chronic myeloid leukemia


Cite item

Full Text

Abstract

To treat patients with different concurrent cancers, including lympho- and myeloproliferative neoplasms, is a difficult task. The paper presents the experience in successfully treating lymphogranulomatosis occurring in a female patient with chronic myeloid leukemia (CML). A combination of the BEACOPP-14 polychemotherapy regimen and imatinib induced no severe complications. Grade 2 neutropenia requiring no use of granulocyte colony-stimulating factors is the only manifestation of hematological toxicity. Infectious complications were successfully eliminated by first-line antimicrobial therapy in the intercourse periods. Remission in lymphogranulomatosis was achieved by polychemotherapy. The authors conclude that the chosen therapy option is effective and relatively safe in treating patients with CML concurrent with lymphogranulomatosis.

Full Text

Успешное лечение лимфомы Ходжкина у больной Ph+ хроническим миелолейкозом. - Аннотация. Лечение больных с сочетанием различных онкологических заболеваний, в том числе лимфо- и миелопролиферативных, является непростой задачей. Приведен опыт успешного лечения лимфогранулематоза, возникшего у пациентки с хроническим миелолейкозом (ХМЛ). Комбинация режима полихимиотерапии BEACOPP-14 и иматиниба не вызвала тяжелых осложнений. Единственным проявлением гематологической токсичности была нейтропения II степени, не потребовавшая применения гранулоцитарных колониестимулирующих факторов. Инфекционные осложнения в межкурсовых периодах успешно купировались противомикробной терапией первого ряда. В результате полихимиотерапии достигнута ремиссия лимфогранулематоза. Авторы делают вывод, что выбранный вариант терапии является эффективным и относительно безопасным у пациентов с сочетанием ХМЛ и лимфогранулематоза.
×

References

  1. Симбирцева Л.П., Холсти Л. Лимфогранулематоз. М: Медицина 1985.
  2. Jaffe E., Harris N., Stein H., Lyon V.J. IACR Press 2001.
  3. DeVita V.T. (eds.), Hellman S., Rosenberg S.A. Cancer: Principles & Practice of Oncology. 6th ed. Vol. 2. Philadelphia: Lippincott - Raven Publishers 2001.
  4. Ries L.A.G., Miller B.A., Hankey B.F. National Cancer Institute. NIH Publication Number 94 1994.
  5. Двойрин В.В., Аксель Е.М., Трапезников Н.Н. Статистика злокачественных новообразований в России и некоторых других странах СНГ. М 1995.
  6. Kaplan H.S. Hodgkin's Disease. Cambridge: Harvard University Press 1980.
  7. Parkin D.M., Muir C.S., Whelan S.L. et al. Scientific Publications N120. Lyon: International Agency for Research on Cancer 1992.
  8. Ramanarayanan J., Dunford L.M., Baer M.R. et al. Chronic myeloid leukemia after treatment of lymphoid malignancies: response to imatinib mesylate and favorable outcomes in three patients. Leuk Res 2006; 30: 6: 701-705.
  9. Aguiar R.C. Therapy-related chronic myeloid leukemia: an epidemiological, clinical and pathogenetic appraisal. Leuk Lymphoma 1998; 29: 1-2: 17-26.
  10. Wintrobe M.M. Tumors and Tumorlike Conditions Involving the Blood-forming Organs in Clinical Hematology, 5th Ed., Lea & Febiger, Philadelphia 1961: 1004-1095.
  11. Greenstein R.H., Conston A.S. Coexistent Hodgkin's disease and Kaposi's sarcoma: Report of a case with unusual clinical features. Am J Med Sci 1949; 218: 384.
  12. Greenberg B.B., Stats D., Goldberg M. Simultaneous occurrence of plasma cell myeloma and Hodgkin's Disease, NY J Med 1950; 50: 305.
  13. Lalayanni C., Theodoridou S., Athanasiadou A. et al. Simultaneous occurrence of multiple myeloma and Hodgkin's disease. A case report. Haematologica 2000; 85: 7: 772-773.
  14. Moertel C.G., Hagedorm A.B. Leukemia or lymphoma and coexistent primary malignant lesions: A review of the literature and a study of 120 cases. Blood 1957; 12: 788.
  15. Nandakumar A., Davis S., Moolgavkar S. et al. Myeloid leukaemia following therapy for a first primary cancer. Br J Cancer 1991; 63: 782-788.
  16. Kaldor J.M., Day N.E., Clarke E.A. et al. Leukemia following Hodgkin's disease. N Engl J Med 1990; 322: 1: 7-13.
  17. Fava C., Cortés J.E., Kantarjian H., Jabbour E. Standard management of patients with chronic myeloid leukemia. Clin Lymphoma Myeloma 2009; 9 (Suppl 4): 382-390.
  18. Ferrario A., Radaelli F., Goldaniga M. et al. ABVD associated with imatinib for coexisting chronic myeloid leukaemia and relapsed Hodgkin lymphoma. Leuk Res 2010; 34: 10: 280-281.
  19. Renné C., Hansmann M.L., Bräuninger A. Receptor tyrosine kinases in Hodgkin lymphoma as possible therapeutic targets. Pathologe 2009; 30: 5: 393-400.
  20. Renné C., Willenbrock K., Küppers R. Autocrine- and paracrine-activated receptor tyrosine kinases in classic Hodgkin lymphoma. Blood 2005; 105: 10: 4051-4059.

Copyright (c) 2012 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies